Eliminating Youth Electronic Cigarette Use: The Role for Drug Therapies Public Hearing

The Food and Drug Administration (FDA or the Agency) is announcing a public hearing to discuss the effort to eliminate youth electronic cigarette (e-cigarette) use as well as other tobacco product use, with a focus on the potential role of drug therapies to support cessation and the issues impacting the development of such therapies.

Date and Location

December 5, 2018

The meeting will be held at:

FDA White Oak Campus 
10903 New Hampshire Avenue
Building 31 Conference Center, Great Room B/C
Silver Spring, MD 20993-0002

The entrance for public meeting participants (non-FDA employees or contractors) is through Building 1, where routine security check procedures will be performed.

For parking, security and other visitor information, please refer to Public Meetings at the FDA White Oak Campus. 

Meeting Information

• The Agenda for the meeting will be posted to this site approximately one week before the public hearing.
• Links to the recorded webcast and meeting transcript will be posted to this website after the meeting.

Registration

Please use Register to attend the event in-person or via webcast at Eventbrite  to register to (1) Attend In-Person (2) Attend In-Person and make a presentation (3) Attend In-Person and make public comment (4) Attend via webcast. Please read ticket descriptions in Eventbrite to make the appropriate selection.

If you need special accommodations due to a disability, please contact Theresa Wells at 703-380-3900 or theresa [dot] wells [at] fda [dot] hhs [dot] gov (theresa[dot]wells[at]fda[dot]hhs[dot]gov) no later than November 23, 2018.

Submitting Comments

Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket by Wednesday, January 2, 2019. Submit electronic comments to Regulations.gov. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

All comments must be identified with the docket number FDA-2018-N-3952. The FDA may post, without change, all comments received to Regulations.gov, including any personal information provided.

Questions

If you have questions about registering for the meeting, contact Theresa Wells, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, phone: 703-380-3900, or email theresa [dot] wells [at] fda [dot] hhs [dot] gov (theresa[dot]wells[at]fda[dot]hhs[dot]gov).